Science Explorer Back to mapMap

Most cited papers from Swedish Dental Association

What are the most cited papers from Swedish Dental Association?

The most cited paper from Swedish Dental Association is "Swedish experience-based value sets for EQ-5D health states" (Kristina Burström, Sun Sun, Ulf‐G. Gerdtham et al., 2013), with 355 citations. Next come "Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions" (122) and "Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries" (122).

Showing 47 of 47 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Swedish experience-based value sets for EQ-5D health states Kristina Burström, Sun Sun, Ulf‐G. Gerdtham et al. · Quality of Life Research Open access 21 Aug 2013 355
2 Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions Rick A. Vreman, Inkatuuli Heikkinen, Ad Schuurman et al. · Value in Health Open access 6 Sep 2019 122
3 Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries Thomas D. Morel, Francis Arickx, Gustaf Befrits et al. · Orphanet Journal of Rare Diseases Open access 2013 122
4 Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness Mikael Svensson, Fredrik Olof Laurentius Nilsson, Karl Arnberg · PharmacoEconomics 20 Jun 2015 117
5 Personalizing health care: feasibility and future implications Brian Godman et al. · BMC Medicine Open access 13 Aug 2013 102
6 MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma Ganna Oliynyk, María Victoria Ruiz-Pérez, Lourdes Sainero‐Alcolado et al. · iScience Open access 11 Oct 2019 100
7 Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment Björn Wettermark, Brian Godman, Martin Neovius et al. · Health Policy 30 Oct 2009 74
8 Access to Healthcare among People with Physical Disabilities in Rural Louisiana Nina Davidsson, Björn Södergård · Social Work in Public Health 16 Mar 2016 70
9 Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI) Jamie Elvidge et al. · Value in Health Open access 23 May 2024 67
10 How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice Giovanni Tafuri, Margherita Pagnini, Jane Moseley et al. · British Journal of Clinical Pharmacology Open access Jun 2016 64
11 Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries Konstantin Tachkov, Antal Tamás Zemplenyi, Maria Kamusheva et al. · Frontiers in Public Health Open access 14 Jul 2022 52
12 Real World Data in Health Technology Assessment of Complex Health Technologies Milou A. Hogervorst, Johan Pontén, Rick A. Vreman et al. · Frontiers in Pharmacology Open access 10 Feb 2022 50
13 A median voter model of health insurance with ex post moral hazard Johanna Jacob, Douglas Lundin · Journal of Health Economics Open access 29 Dec 2004 50
14 Why Did Drug Spending Increase During the 1990s? Ulf‐G. Gerdtham, Douglas Lundin · PharmacoEconomics 2004 49
15 Pricing of oral generic cancer medicines in 25 European countries; findings and implications Brian Godman et al. · Generics and Biosimilars Initiative Journal Open access 15 Jun 2019 45
16 Essential to increase the use of generics in Europe to maintain comprehensive health care? Brian Godman, Marion Bennie, Christoph Baumgärtel et al. · Farmeconomia Health economics and therapeutic pathways Open access 5 Dec 2012 40
17 The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations Giovanni Tafuri et al. · British Journal of Clinical Pharmacology Open access 25 Jan 2018 39
18 Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden Brian Godman, Marie Persson, Jamilette Miranda et al. · Applied Health Economics and Health Policy 10 Jun 2013 33
19 Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making Margreet G. Franken, Fredrik Olof Laurentius Nilsson, Frank Sandmann et al. · PharmacoEconomics 9 Jul 2013 30
20 On survival consumption costs – a reply to Nyman Douglas Lundin, Joakim Ramsberg · Health Economics 21 Sep 2007 24
21 Assessment of the Swedish EQ-5D experience-based value sets in a total hip replacement population Szilárd Nemes, Kristina Burström, Niklas Zethraeus et al. · Quality of Life Research 2 Jun 2015 21
22 Cost-Effectiveness of School-Based Prevention of Cannabis Use Charlotte L. Deogan, Natalie Zarabi, Nils Stenström et al. · Applied Health Economics and Health Policy 13 May 2015 21
23 Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden Joakim Ramsberg, Stefan Odeberg, Andreas Engstr�m et al. · The European Journal of Health Economics 21 Aug 2004 18
24 Low persistence of anticholinergic drug use in Sweden Love Linnér, Helena Schiöler, Eva C. Samuelsson et al. · European Journal of Clinical Pharmacology 8 Nov 2010 18
25 Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future Brian Godman et al. · Generics and Biosimilars Initiative Journal Open access 15 Sep 2015 15
26 The impact of health economic evaluations in Sweden Emelie Heintz, Karl Arnberg, Lars‐Åke Levin et al. · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen 2014 14
27 Cost‐effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry Fredrik Olof Laurentius Nilsson, Love Linnér, Eva C. Samuelsson et al. · British Journal of Urology 17 Nov 2011 14
28 Delayed payment schemes in Central-Eastern Europe and Middle-East Ildikó Ádám, Marcelien Callenbach, Bertalan Németh et al. · Frontiers in Medicine Open access 12 Aug 2022 13
29 Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers Maria Kamusheva, Bertalan Németh, Antal Tamás Zemplenyi et al. · Journal of Comparative Effectiveness Research Open access 21 Jun 2022 12
30 The ageing of society, health services provision and taxes Ulf‐G. Gerdtham, Douglas Lundin, María Sáez‐Martí · Journal of Population Economics Sep 2005 10
31 Implementing a sandbox approach in health technology assessment: benefits and recommendations Jamie Elvidge, Nick Crabb, Diana M. J. Delnoij et al. · International Journal of Technology Assessment in Health Care Open access 2024 9
32 Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe Tuba Saygın Avşar, Jamie Elvidge, Claire Hawksworth et al. · Value in Health Open access 31 Jul 2024 9
33 Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision making Ashley A. Jaksa, Alina N Pavel, Matti Aapro et al. · International Journal of Technology Assessment in Health Care Open access 2025 6
34 Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease Jacoline C. Bouvy, Pall F. Jonsson, Diana O'Rourke et al. · CNS Drugs Open access 22 Nov 2018 5
35 Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012) Thomas D. Morel, Francis Arickx, Gustaf Befrits et al. · Value in Health Open access 22 Oct 2013 5
36 Variation in the prices of oncology medicines across Europe and the implications for the future Brian Godman et al. · Generics and Biosimilars Initiative Journal Open access 15 Jun 2021 4
37 Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European Countries Zoltán Kaló et al. · Health Science Reports Open access 27 Jan 2026 3
38 Reimbursement Decisions for Pharmaceuticals in Sweden: the Impact of Cost-Effectiveness and Disease Severity Fredrik Olof Laurentius Nilsson, Mikael Svensson, Karl Arnberg · Value in Health Open access 26 Oct 2014 3
39 Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation Dominik Karres et al. · British Journal of Pharmacology Open access 22 Nov 2024 2
40 Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained Jonas Björnerstedt, Hannah Almqvist, Douglas Lundin et al. · Journal of Medical Economics Open access 16 Jan 2024 1
41 Patient preference of ostomy pouching systems – focus group interviews with stoma care patients Björn Södergård, I. Tredal, I. Hemmingsson et al. · Value in Health Open access May 2014 1
42 Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance Luis Correia Pinheiro, Amanda C. Langston, Marie Orre et al. · Clinical Pharmacology & Therapeutics Open access 13 Aug 2026 0
43 Regulatory research priorities for AI use in the medicine lifecycle: a European perspective with global relevance Luis Pinheiro, Amanda Langston, Marie Orre et al. · Zenodo (CERN European Organization for Nuclear Research) Open access 13 Aug 2026 0
44 The relationship between practice ownership and follow-up of comprehensive dental care. A Swedish register study Bengt Franzon, Mikael Moutakis, Björn Axtelius et al. · Acta Odontologica Scandinavica Open access 16 Apr 2024 0
45 Cost-effectiveness in Swedish reimbursement decision making Andreas Engström · European Journal of Pharmaceutical Sciences 30 Apr 2008 0
46 RE2 A Detailed Comparison of Dutch and Swedish Drug Reimbursement Decisions: What Evidence is Available, Which Criteria are Used, and is the Decision-Making Process Transparent? Margreet G. Franken, Fredrik Olof Laurentius Nilsson, Frank Sandmann et al. · Value in Health Open access 29 Oct 2012 0
47 A comparative study of reimbursement application patterns between Iceland and Sweden Fredrik Olof Laurentius Nilsson, Rúna Hauksdottir, Sveinbjorn Högnason · Journal of Pharmaceutical Health Services Research Mar 2011 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.